|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STK38L |
Gene summary for STK38L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STK38L | Gene ID | 23012 |
| Gene name | serine/threonine kinase 38 like | |
| Gene Alias | NDR2 | |
| Cytomap | 12p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9Y2H1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23012 | STK38L | LZE4T | Human | Esophagus | ESCC | 5.76e-06 | 1.59e-01 | 0.0811 |
| 23012 | STK38L | LZE5T | Human | Esophagus | ESCC | 9.49e-03 | 3.89e-01 | 0.0514 |
| 23012 | STK38L | LZE7T | Human | Esophagus | ESCC | 2.67e-06 | 5.49e-01 | 0.0667 |
| 23012 | STK38L | LZE8T | Human | Esophagus | ESCC | 2.02e-12 | 4.27e-01 | 0.067 |
| 23012 | STK38L | LZE20T | Human | Esophagus | ESCC | 8.58e-07 | 9.04e-02 | 0.0662 |
| 23012 | STK38L | LZE24T | Human | Esophagus | ESCC | 3.67e-08 | 4.33e-01 | 0.0596 |
| 23012 | STK38L | LZE21T | Human | Esophagus | ESCC | 3.91e-05 | 1.50e-01 | 0.0655 |
| 23012 | STK38L | P1T-E | Human | Esophagus | ESCC | 1.16e-02 | 1.28e-01 | 0.0875 |
| 23012 | STK38L | P2T-E | Human | Esophagus | ESCC | 2.14e-34 | 7.34e-01 | 0.1177 |
| 23012 | STK38L | P4T-E | Human | Esophagus | ESCC | 3.78e-31 | 1.18e+00 | 0.1323 |
| 23012 | STK38L | P5T-E | Human | Esophagus | ESCC | 6.51e-04 | 9.96e-02 | 0.1327 |
| 23012 | STK38L | P8T-E | Human | Esophagus | ESCC | 8.90e-35 | 6.83e-01 | 0.0889 |
| 23012 | STK38L | P9T-E | Human | Esophagus | ESCC | 2.12e-09 | 1.71e-01 | 0.1131 |
| 23012 | STK38L | P10T-E | Human | Esophagus | ESCC | 7.55e-21 | 3.74e-01 | 0.116 |
| 23012 | STK38L | P12T-E | Human | Esophagus | ESCC | 3.55e-36 | 7.54e-01 | 0.1122 |
| 23012 | STK38L | P15T-E | Human | Esophagus | ESCC | 1.61e-08 | 3.17e-01 | 0.1149 |
| 23012 | STK38L | P16T-E | Human | Esophagus | ESCC | 1.45e-90 | 2.10e+00 | 0.1153 |
| 23012 | STK38L | P17T-E | Human | Esophagus | ESCC | 4.22e-05 | 1.50e-01 | 0.1278 |
| 23012 | STK38L | P19T-E | Human | Esophagus | ESCC | 3.59e-04 | 5.95e-01 | 0.1662 |
| 23012 | STK38L | P20T-E | Human | Esophagus | ESCC | 6.98e-13 | 4.59e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:00182098 | Oral cavity | OSCC | peptidyl-serine modification | 175/7305 | 338/18723 | 1.09e-06 | 1.46e-05 | 175 |
| GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
| GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
| GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
| GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
| GO:001820922 | Oral cavity | NEOLP | peptidyl-serine modification | 72/2005 | 338/18723 | 7.84e-09 | 4.09e-07 | 72 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STK38L | SNV | Missense_Mutation | c.108N>G | p.Ile36Met | p.I36M | Q9Y2H1 | protein_coding | tolerated(0.65) | benign(0.127) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| STK38L | SNV | Missense_Mutation | novel | c.416G>T | p.Arg139Ile | p.R139I | Q9Y2H1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| STK38L | SNV | Missense_Mutation | novel | c.261N>T | p.Leu87Phe | p.L87F | Q9Y2H1 | protein_coding | tolerated(0.07) | benign(0.03) | TCGA-AC-A23E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| STK38L | SNV | Missense_Mutation | rs746501951 | c.215N>A | p.Arg72His | p.R72H | Q9Y2H1 | protein_coding | deleterious(0.01) | benign(0.238) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| STK38L | SNV | Missense_Mutation | c.839N>T | p.Ala280Val | p.A280V | Q9Y2H1 | protein_coding | deleterious(0.01) | possibly_damaging(0.85) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STK38L | SNV | Missense_Mutation | c.1307G>T | p.Trp436Leu | p.W436L | Q9Y2H1 | protein_coding | tolerated(1) | benign(0.042) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| STK38L | insertion | Nonsense_Mutation | novel | c.480_481insCAAAGCCAGGATCCTAGGCTGGGTAGAGATTCTGGTTAAAAAGTTGTT | p.Lys160_Arg161insGlnSerGlnAspProArgLeuGlyArgAspSerGlyTerLysValVal | p.K160_R161insQSQDPRLGRDSG*KVV | Q9Y2H1 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| STK38L | SNV | Missense_Mutation | c.697N>C | p.Gly233Arg | p.G233R | Q9Y2H1 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STK38L | SNV | Missense_Mutation | novel | c.717N>T | p.Lys239Asn | p.K239N | Q9Y2H1 | protein_coding | tolerated(0.11) | probably_damaging(0.991) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STK38L | SNV | Missense_Mutation | c.108N>G | p.Ile36Met | p.I36M | Q9Y2H1 | protein_coding | tolerated(0.65) | benign(0.127) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23012 | STK38L | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565890 | ||
| 23012 | STK38L | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |